This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Inks Deal With Eurofarma to Make COVID-19 Vaccine
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech ink a collaboration deal with Brazil's Eurofarma for manufacturing and supplying their COVID-19 vaccine, Comirnaty, in Latin America.
Airline Stock Roundup: LUV's Tentative Labor Deal, DAL's Fleet Upgrade & More
by Maharathi Basu
Southwest Airlines (LUV) inks a tentative labor deal on its customer-service employees. Delta (DAL) places an order for more A321neo jets.
Biotech Stock Roundup: REGN, MRNA Offer COVID-19 Updates, TBPH Down on Study Update
by Zacks Equity Research
Regulatory and pipeline updates from Regeneron (REGN) and Moderna (MRNA), among others have been in focus in the biotech industry over the past week.
Pfizer (PFE), BioNTech Seek Full Approval for COVID Jab Booster
by Zacks Equity Research
The booster dose of Pfizer (PFE)/BioNTech's (BNTX) mRNA-based COVID-19 vaccine, Comirnaty dose induced significant SARS-CoV-2 neutralizing antibody titers in phase III study.
J&J (JNJ) Reports Positive Interim Data on COVID Booster Jab
by Zacks Equity Research
The booster dose of J&J's (JNJ) single-shot COVID-19 vaccine achieves rapid and robust increase in spike-binding antibodies in previously vaccinated people with the initial dose.
Moderna (MRNA) Seeks Full FDA Approval for COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) completes rolling submission of BLA to the FDA seeking full approval of its COVID-19 vaccine candidate, mRNA-1273, in the United States.
ETFs to Rise on Full FDA Approval for Pfizer COVID-19 Vaccine
by Sweta Jaiswal, FRM
Let's look at the ETFs that are well-poised to gain as Comirnaty's full FDA approval is likely to drive the vaccination rate.
Will CARZ ETF Gain Despite Mixed Auto Earnings?
by Sweta Jaiswal, FRM
Let's take a look at the impact of major automakers' earnings releases on automobile ETF amid the coronavirus crisis.
Stock Market News for Aug 25, 2021
by Zacks Equity Research
U.S. stocks continued their winning-run on Tuesday supported by the FDA¿¿¿s first full approval of COVID-19 vaccines.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Johnson & Johnson and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Johnson & Johnson and Novavax
6 Must-Buy Corporate Giants As Major Indexes Hit Record High
by Nalak Das
We have narrowed down our search to six stocks that are members of any of the three major indexes. These are: MRNA, NVDA, TJX, AAPL, DE and REGN.
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On (Revised)
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
Nasdaq Crosses 15K for 1st Time Ever; JWN, URBN Beat
by Mark Vickery
On the way to its fourth-straight up day in the market, the tech-heavy Nasdaq wound up surpassing 15K for its first time ever.
Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs
by Sweta Jaiswal, FRM
The biotech space has once again come under the spotlight as the FDA has granted the first full U.S. approval to Pfizer (PFE)/BioNTech's (BNTX) coronavirus vaccine.
Dynavax (DVAX) Gains as Medigen Rolls Out COVID-19 Vaccine
by Zacks Equity Research
Dynavax (DVAX) stock gains as partner Medigen announces launch of its COVID-19 vaccine MVC-COV1901 adjuvanted with CpG 1018 of the former.
Stock Market News for Aug 24, 2021
by Zacks Equity Research
U.S. stock markets rallied on Monday after a disappointing last week.
3 COVID Vaccine Makers to Watch on Pfizer Jab Full FDA Approval
by Zacks Equity Research
Stocks of coronavirus vaccine makers BNTX and MRNA fly high following complete approval of Pfizer's COVID-19 vaccine. The momentum is likely to continue for these stocks. JNJ is another strong contender in this field.
Pfizer (PFE)/BioNTech Comirnaty Gets FDA's Full Approval
by Zacks Equity Research
Pfizer (PFE)/BioNTech's (BNTX) mRNA-based COVID-19 vaccine, Comirnaty becomes the first vaccine to be granted full approval by the FDA.
Top 5 High-Yielding Stock Market Gainers YTD With More Upside
by Nalak Das
We have narrowed down our search to five large-cap stocks (market capital >$30 billion) that have popped more than 30% year to date. These are: AIG, MET, BX, COP and EOG.
Markets Surge on Pfizer Vax Approval
by Mark Vickery
Led by shares of BioNTech (BNTX), which gained +9.6% on the day, the Nasdaq zoomed ahead to its single-best trading day since May 20th and finished at a brand new all-time high close.
Markets Bounce Back as Slow Summer Weeks Are Here
by Mark Vickery
Fewer than 90 companies are scheduled to release earnings this week, and at first glance none look to represent the S&P 500.
Wall Street Waits For The Fed's Big Event
by Zacks Equity Research
Wall Street Waits For The Fed's Big Event.
Valneva (VALN) Begins Submission for COVID-19 Vaccine in UK
by Zacks Equity Research
Valneva (VALN) starts rolling submission for the initial approval of its COVID-19 vaccine candidate, VLA2001, in the United Kingdom.
Biotech ETFs to Benefit From Latest Booster Update
by Sweta Jaiswal, FRM
The U.S. government's plans to make COVID-19 vaccine booster shots available from next month will likely increase the profits of vaccine makers.
Is Moderna (MRNA) COVID-19 Jab Heart Risk More Than Pfizer's?
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine is being probed for higher risk of heart inflammation compared to Pfizer's vaccine, per a Washington Post article.